Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000554385 | SCV000658467 | uncertain significance | Multiple endocrine neoplasia, type 2 | 2025-01-11 | criteria provided, single submitter | clinical testing | This sequence change replaces aspartic acid, which is acidic and polar, with asparagine, which is neutral and polar, at codon 102 of the RET protein (p.Asp102Asn). This variant is present in population databases (rs201244749, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with RET-related conditions. ClinVar contains an entry for this variant (Variation ID: 135183). An algorithm developed to predict the effect of missense changes on protein structure and function outputs the following: PolyPhen-2: "Probably Damaging". The asparagine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV000567241 | SCV000674850 | benign | Hereditary cancer-predisposing syndrome | 2023-02-02 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Prevention |
RCV004528836 | SCV000807043 | uncertain significance | RET-related disorder | 2023-04-20 | criteria provided, single submitter | clinical testing | The RET c.304G>A variant is predicted to result in the amino acid substitution p.Asp102Asn. This variant has been reported in individuals from a healthy, ancestrally diverse genome sequencing cohort (Table S1, Bodian et al. 2014. PubMed ID: 24728327). In silico tools predict this variant to be tolerated (Table S1, George Priya Doss et al. 2014. PubMed ID: 24336963; Table 1, Heineman et al . 2015. PubMed ID: 25733075). This variant is reported in 0.017% of alleles in individuals of South Asian descent in gnomAD (http://gnomad.broadinstitute.org/variant/10-43596137-G-A) and has conflicting interpretations of benign and uncertain significance in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/135183/). Although we suspect this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |
Fulgent Genetics, |
RCV002483229 | SCV002777708 | uncertain significance | Hirschsprung disease, susceptibility to, 1; Multiple endocrine neoplasia type 2B; Pheochromocytoma; Familial medullary thyroid carcinoma; Multiple endocrine neoplasia type 2A | 2022-02-12 | criteria provided, single submitter | clinical testing | |
ITMI | RCV000121987 | SCV000086198 | not provided | not specified | 2013-09-19 | no assertion provided | reference population |